|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash Flows Used In Operating Activities | |||||
| Net Loss | |||||
| Non-Cash Adjustments | |||||
| Depreciation and Amortization | |||||
| Stock-Based Compensation | |||||
| Impairment of Patents and Trademarks | |||||
| Loss on Fixed Asset Disposal | |||||
| Allowance for Credit Losses | |||||
| Inventory Reserves for Obsolescence | |||||
| Loss on Goodwill and Other Intangible Asset Impairment | |||||
| Impairment on Goodwill, Intangible Assets, and Equity Investments | |||||
| (Increase) Decrease in Operating Assets | |||||
| Accounts Receivable | |||||
| Accrued Revenues in Excess of Billings | |||||
| Other Receivables | |||||
| Inventories | |||||
| Manufacturing Vendor Prepayments | |||||
| Prepaid Expenses and Other Assets | |||||
| Increase (Decrease) in Operating Liabilities | |||||
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Unearned Revenue | |||||
| Income and Other Taxes Payable | |||||
| Net Cash Flows Used in Operating Activities | |||||
| Cash Flows Used in Investing Activities | |||||
| Purchases of Fixed Assets | |||||
| Investments in Patents and Trademarks | |||||
| Investments in Licenses | |||||
| Investments in Software Development | |||||
| Investment in Atomistic | |||||
| Investments in Other Equity Assets | |||||
| Net Cash Flows Used in Investing Activities | |||||
| Cash Flows Provided by (Used in) Financing Activities | |||||
| Proceeds from Sale of Preferred and Common Stock to Quanta | |||||
| Proceeds from Exercise of Stock Options | |||||
| Proceeds from ATM Program, Net | |||||
| Security purchase agreement with quanta computer inc | |||||
| ATM Offering | |||||
| Total proceeds from ATM Program, Net | |||||
| Purchase of Treasury Stock | |||||
| Preferred Dividends Paid | |||||
| Net Cash Flows Provided by (Used in) Financing Activities | |||||
| Net Increase (Decrease) in Cash and Cash Equivalents | |||||
| Cash and Cash Equivalents - Beginning of Period | |||||
| Cash and Cash Equivalents - End of Period | |||||
| Supplemental Disclosures | |||||
| Non-Cash Investment in Licenses | |||||
| Investment in Atomistic - Equity issued | |||||
| Accrued Preferred Dividends included in Accrued Expenses | |||||
| Depreciation and Amortization included in Research and Development Expense | |||||
| Stock-Based Compensation Expense - Expensed less Previously Issued | |||||
| Purchases of Fixed Assets included in Accrued Expenses | |||||
Loading...